Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2017-02-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于延长Xcovery公司可转换公司债兑付期限暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the extension of the repayment period for convertible bonds subscribed to Xcovery Holding Company LLC. It details the background of the investment, the board and shareholder approvals, the strategic purpose of the extension, and related party disclosures. The document is an announcement of a financing-related event (extension of convertible bond repayment) and includes information about the transaction and its impact. It does not contain comprehensive financial statements or detailed financial performance data, nor is it a full report or audit. The document length is 2673 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-02-28 Chinese
第二届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 贝达药业股份有限公司 regarding the extension of the maturity date of a convertible bond investment in Xcovery company. It includes details about the meeting, voting results, and the decision made. The document is short (1161 characters) and is an official announcement of a board meeting resolution rather than a full financial report or detailed management discussion. It does not contain financial statements or detailed financial data. It is not an annual or interim report, nor an earnings release. It is not a proxy statement or voting results announcement for shareholders, but a board/management information announcement about a specific decision. Therefore, the best fitting category is Board/Management Information (MANG).
2017-02-28 Chinese
独立董事关于第二届董事会第八次会议相关事项的事前认可和独立意见
Board/Management Information Classification · 95% confidence The document is a formal statement from independent directors regarding their prior approval and independent opinion on a specific board meeting matter, specifically about extending the maturity of convertible bonds related to a related party. It references regulatory guidelines for independent directors and board meeting procedures. The content focuses on governance and board-level decision-making rather than financial results, audit, or shareholder voting outcomes. The document length is short (1014 characters) and does not contain financial statements or detailed financial data. It is not an announcement of voting results or a proxy solicitation. It is best classified as Board/Management Information (MANG) because it relates to board meeting matters and independent directors' opinions on corporate governance issues.
2017-02-28 Chinese
第二届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 8th meeting of the 2nd Board of Directors of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and the voting results on specific proposals, including investment and financing decisions. The content focuses on board meeting procedures and decisions rather than financial results, audit opinions, or regulatory filings. There is no indication of it being an annual report, audit report, earnings release, or other financial report. It is clearly a Board/Management Information announcement about board meeting resolutions and decisions. The document length is short (2010 characters), consistent with a meeting resolution announcement rather than a full report. Therefore, the appropriate classification is MANG (Board/Management Information).
2017-02-28 Chinese
卡南吉医药科技（上海）有限公司审计报告（2016年1月1日至2017年1月31日止）
Regulatory Filings
2017-02-27 Chinese
2016年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2016 年度业绩快报' which translates to '2016 Annual Performance Express Report' or '2016 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2016, including revenue, profit, net income, earnings per share, and asset information. The document explicitly states that the data is preliminary and unaudited, and that the final audited data will be disclosed in the annual report. The length of the document is 2007 characters, which is relatively short and typical for an earnings release or earnings quick report rather than a full annual report. The document does not contain full financial statements or detailed analysis but provides key highlights and performance metrics. According to the filing definitions, an Earnings Release (ER) is the initial announcement of quarterly or periodical financial results with key highlights only, which fits this document. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and audit. It is also not a Report Publication Announcement (RPA) because it contains actual preliminary financial data, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER). FY 2016
2017-02-27 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.